Smith & Nephew plc

NYSE:SNN

Medical - Devices

Healthcare
$30.32 -1.39%

-$0.43 today

Market cap
$12.72B
Beta
0.67
P/E (TTM)
20.1
EPS (TTM)
$0.74
Dividend yield
2.59%
52W Low $28.79High $38.79

Volume 1.22M

Average 1.10M

SNN Income Tax Expense

Income taxes recognized for the period, including current and deferred tax.

Smith & Nephew plcNYSE: SNN

Income Tax Expense · Q4 FY2025 · quarter ended Dec 2025

Income tax expense grows 80.9% year over year

Q4 FY2025 income tax expense of $85M rose 80.9% year over year. Over 3 fiscal years it compounded at +134.1% a year.

Context

  • Income tax expense amounted to 2.5% of revenue in FY2025, up 1.0 pp from a year earlier.
  • Income tax expense increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterDec 2025
$85M— QoQ
Last fiscal yearDec 2025
$154M+79.1% YoY
Income Tax Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+80.9%——
1 year+79.1%——
3-year CAGR+134.1%——
5-year CAGR——
10-year CAGR——

Income Tax Expense history

USD · from the income statement

Latest · FY2025
154M USD
Year-over-year change
+79.1%
4-year CAGR
+25.5%

Income Tax Expense vs competitors

How SNN compares with its peers on the latest reported figures

  • SNN's FY2025 income tax expense of $154M is the 2nd highest of the 11 companies compared; the peer median is $14.52M.
  • Its year-over-year change of +79.1% is the 6th highest of 11, against a peer median of +66.1%.
  • Income tax expense amounts to 2.5% of revenue for SNN, versus a peer median of 1.6%.
SNN Competitors Peer median
Income Tax Expense for SNN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SYKStryker CorporationLTM Jun 2026$1.42B +227.7%+57.4%5.5%
SNNSmith & Nephew plcFY2025$154M +79.1%+134.1%2.5%
GMEDGlobus Medical, Inc.LTM Jun 2026$129.49M +666.6%+10.9%4.1%
ZBHZimmer Biomet Holdings, Inc.LTM Jun 2026$126.6M -14.3%+3.8%1.5%
ENOVEnovis CorporationLTM Apr 2026$33.11M +226.9%-14.9%1.5%
CNMDCONMED CorporationLTM Mar 2026$26.95M +1.6%+35.3%2.0%
XTNTXtant Medical Holdings, Inc.LTM Mar 2026$2.08M +2112.8%+208.6%1.7%
OFIXOrthofix Medical Inc.LTM Mar 2026$495K -77.8%-12.2%0.1%
KIDSOrthoPediatrics Corp.LTM Mar 2026$93K +106.7%—0.0%
ATECAlphatec Holdings, Inc.LTM Mar 2026$69K +25.5%—0.0%
IARTIntegra LifeSciences Holdings CorporationLTM Mar 2026-$40.08M -184.5%—2.4%
Peer median (excluding SNN) $14.52M+66.1%+10.9%1.6%

Competitors are the stored peer set for SNN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue5.21B5.22B5.55B5.81B6.16B
Cost of Revenue1.51B1.52B1.65B1.73B1.96B
Gross Profit3.7B3.7B3.9B4.08B4.21B
Gross Margin71.0%70.9%70.2%70.2%68.3%
Research & Development356M345M339M343M346M
Selling, General & Admin2.64B2.71B2.83B2.9B3.04B
Operating Expenses3.11B3.25B3.47B3.42B3.41B
Depreciation & Amortization507M492M473M449M459M
EBITDA1.22B1.15B1.21B1.34B1.34B
EBITDA Margin23.4%22.1%21.9%23.0%21.7%
Operating Income593M450M425M657M794M
Operating Margin11.4%8.6%7.7%11.3%12.9%
Interest Income6M13.99M34.13M24.01M28.07M
Interest Expense79.99M79.95M132.51M150.06M141.33M
Other Income / Expenses(7M)(215M)(135M)(159M)(15M)
Income Before Tax586M235M290M498M779M
Pre-Tax Margin11.2%4.5%5.2%8.6%12.6%
Income Tax Expense62M12M27M86M154M
Net Income524M223M263M412M625M
Net Margin10.1%4.3%4.7%7.1%10.1%
EPS (Basic)1.200.501.200.941.46
EPS (Diluted)1.200.501.200.941.44
Weighted Avg Shares438.5M437.55M217.75M438.3M433.42M
Weighted Avg Shares (Diluted)438.86M437.55M218.44M438.3M436.47M

Smith & Nephew plc

NYSE:SNN

Intrinsic Alpha fair value

Locked

Current Price

$30.32

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.